IBIO Quote, Financials, Valuation and Earnings

Nanoviricides has a net margin of -4444.57% compared to iBio's net margin of --. iBio's return on equity of -148.3% beat Nanoviricides's return on equity of --.

iBio has a consensus price target of --, signalling upside risk potential of 52.54%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 324.84%. Given that Nanoviricides has higher upside potential than iBio, analysts believe Nanoviricides is more attractive than iBio.

iBio has a beta of -3.237, which suggesting that the stock is 423.713% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.355%.

iBio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iBio pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

iBio quarterly revenues are $175K, which are larger than Nanoviricides quarterly revenues of --. iBio's net income of -$4M is lower than Nanoviricides's net income of -$3.1M. Notably, iBio's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iBio is -- versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -4444.57% compared to iBio's net margin of --. iBio's return on equity of -148.3% beat Oragenics's return on equity of --.

iBio has a consensus price target of --, signalling upside risk potential of 52.54%. On the other hand Oragenics has an analysts' consensus of -- which suggests that it could grow by 24523.8%. Given that Oragenics has higher upside potential than iBio, analysts believe Oragenics is more attractive than iBio.

iBio has a beta of -3.237, which suggesting that the stock is 423.713% less volatile than S&P 500. In comparison Oragenics has a beta of 0.434, suggesting its less volatile than the S&P 500 by 56.551%.

iBio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iBio pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

iBio quarterly revenues are $175K, which are larger than Oragenics quarterly revenues of --. iBio's net income of -$4M is lower than Oragenics's net income of -$2.5M. Notably, iBio's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iBio is -- versus 1.44x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -4444.57% compared to iBio's net margin of -2357.27%. iBio's return on equity of -148.3% beat Palatin Technologies's return on equity of --.

iBio has a consensus price target of --, signalling upside risk potential of 52.54%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1652.58%. Given that Palatin Technologies has higher upside potential than iBio, analysts believe Palatin Technologies is more attractive than iBio.

iBio has a beta of -3.237, which suggesting that the stock is 423.713% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

iBio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iBio pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

iBio quarterly revenues are $175K, which are smaller than Palatin Technologies quarterly revenues of $350K. iBio's net income of -$4M is higher than Palatin Technologies's net income of -$7.8M. Notably, iBio's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iBio is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -4444.57% compared to iBio's net margin of --. iBio's return on equity of -148.3% beat Theriva Biologics's return on equity of --.

iBio has a consensus price target of --, signalling upside risk potential of 52.54%. On the other hand Theriva Biologics has an analysts' consensus of $100.00 which suggests that it could grow by 6861.54%. Given that Theriva Biologics has higher upside potential than iBio, analysts believe Theriva Biologics is more attractive than iBio.

iBio has a beta of -3.237, which suggesting that the stock is 423.713% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.329, suggesting its more volatile than the S&P 500 by 32.874%.

iBio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iBio pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

iBio quarterly revenues are $175K, which are larger than Theriva Biologics quarterly revenues of --. iBio's net income of -$4M is higher than Theriva Biologics's net income of -$7.7M. Notably, iBio's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iBio is -- versus 0.90x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.